title: Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections.
abstract: BACKGROUND
  Paramyxovirus (PV) infections are increasingly recognized in lung transplant recipients and have been linked to subsequent graft failure and bronchiolitis obliterans syndrome (BOS). Ribavirin represents a possible treatment option although the outcome on graft function and BOS incidence is unknown.
  
  
  METHODS
  We analysed outcomes of all PV infections in lung/heart-lung recipients between September 2006 and April 2009 in a single centre. PV-infected recipients treated with oral ribavirin were compared with those unable to receive ribavirin due to contraindications. Recovery of graft function, time to recovery and new development of BOS were compared.
  
  
  RESULTS
  A total of 38 patients (ribavirin group) were treated with ribavirin for a median of 9 days (IQR 8-12), whilst 29 patients (non-ribavirin group) received best supportive care including corticosteroids. The median forced expiratory volume in 1 s dropped 20% (IQR 15-32) from baseline in the ribavirin group versus 18% (IQR 13-30) in the non-ribavirin group during infection. In 84% of patients treated with ribavirin and 59% of the non-ribavirin group, graft function recovered within 30 days (P=0.02). New onset of BOS developed within 6 months in 5% of the ribavirin group versus 24% of the non-ribavirin group (P=0.02).
  
  
  CONCLUSIONS
  Treatment of PV after lung/heart-lung transplantation with oral ribavirin seems to be associated with earlier recovery of graft function and to prevent BOS.
authors.affiliation: Department of Respiratory Medicine, Medical School Hannover, Hannover, Germany. fuehner.thomas@mh-hannover.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Fuehner
authors.forename: Martin
authors.initials: M
authors.lastname: Dierich
authors.forename: Christoph
authors.initials: C
authors.lastname: Duesberg
authors.forename: Claudia
authors.initials: C
authors.lastname: DeWall
authors.forename: Tobias
authors.initials: T
authors.lastname: Welte
authors.forename: Axel
authors.initials: A
authors.lastname: Haverich
authors.forename: Gregor
authors.initials: G
authors.lastname: Warnecke
authors.forename: Andre R
authors.initials: AR
authors.lastname: Simon
authors.forename: Jens
authors.initials: J
authors.lastname: Gottlieb
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000821:virology; D035061:Control Groups; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D012137:Respiratory System / Q000473:pathology / Q000821:virology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy*; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012577:Schools, Medical; D013147:Spirometry; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D005938:Glucocorticoids; D012254:Ribavirin